menu
    • menu
    [{"orgOrder":0,"company":"Shenzhen Chipscreen Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"CS12192","moa":"JAK3\/JAK1","graph1":"Immunology","graph2":"IND Enabling","graph3":"Shenzhen Chipscreen Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Shenzhen Chipscreen Biosciences \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Shenzhen Chipscreen Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Shenzhen Chipscreen Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Chiauranib","moa":"VEGFR","graph1":"Oncology","graph2":"Phase III","graph3":"Shenzhen Chipscreen Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Shenzhen Chipscreen Biosciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Shenzhen Chipscreen Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Shenzhen Chipscreen Biosciences","sponsor":"HUYA Bioscience International","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Chidamide","moa":"HDAC","graph1":"Oncology","graph2":"Phase II","graph3":"Shenzhen Chipscreen Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Shenzhen Chipscreen Biosciences \/ Shenzhen Chipscreen Biosciences","highestDevelopmentStatusID":"8","companyTruncated":"Shenzhen Chipscreen Biosciences \/ Shenzhen Chipscreen Biosciences"},{"orgOrder":0,"company":"Shenzhen Chipscreen Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"NWY001","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Shenzhen Chipscreen Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Shenzhen Chipscreen Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Shenzhen Chipscreen Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Shenzhen Chipscreen Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"CHINA","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Chiglitazar Sodium","moa":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Shenzhen Chipscreen Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Shenzhen Chipscreen Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Shenzhen Chipscreen Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Shenzhen Chipscreen Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"CS32582","moa":"","graph1":"Dermatology","graph2":"Phase I","graph3":"Shenzhen Chipscreen Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Shenzhen Chipscreen Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Shenzhen Chipscreen Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Shenzhen Chipscreen Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Chidamide","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Shenzhen Chipscreen Biosciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Shenzhen Chipscreen Biosciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Shenzhen Chipscreen Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Shenzhen Chipscreen Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Chiglitazar Sodium","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Shenzhen Chipscreen Biosciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Shenzhen Chipscreen Biosciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Shenzhen Chipscreen Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Shenzhen Chipscreen Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"CS231295","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Shenzhen Chipscreen Biosciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Shenzhen Chipscreen Biosciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Shenzhen Chipscreen Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Shenzhen Chipscreen Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Chiauranib","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Shenzhen Chipscreen Biosciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Shenzhen Chipscreen Biosciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Shenzhen Chipscreen Biosciences \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Shenzhen Chipscreen Biosciences

    Menu

    Shenzhen Chipscreen Biosciences

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Shenzhen Chipscreen Biosciences

                            China arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Shenzhen Chipscreen Biosciences

                            China arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Chiauranib,Monoclonal Antibody-based Therapy

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Phase III Chiauranib Trial Approved for Extensive Disease Small Cell Lung Cancer

                            Details : CS-2164 (chiauranib) is a novel molecular entity and a selective inhibitor of Aurora B, a key mitotic regulator, being developed for the first-line treatment of extensive stage small cell lung cancer.

                            Brand Name : CS-2164

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            November 01, 2024

                            Lead Product(s) : Chiauranib,Monoclonal Antibody-based Therapy

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Shenzhen Chipscreen Biosciences

                            China arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Shenzhen Chipscreen Biosciences

                            China arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CS231295

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Chipscreen’s IND Application Accepted for Anti-Tumor Drug CS231295

                            Details : CS231295 is a novel brain-penetrating small-molecule, multi-target protein kinase inhibitor, which is being evaluated for the treatment of neoplasms.

                            Brand Name : CS231295

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 17, 2024

                            Lead Product(s) : CS231295

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Shenzhen Chipscreen Biosciences

                            China arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Shenzhen Chipscreen Biosciences

                            China arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Chiglitazar Sodium,Metformin

                            Therapeutic Area : Endocrinology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Chiglitazar and Metformin Approved by NMPA for Type 2 Diabetes Treatment

                            Details : NMPA approved Chiglitazar, a noval PPAR (Peroxidase Proliferator Activated Receptor) full agonist developed by the company independently, combined with Metformin for the treatment of type 2 diabetes.

                            Brand Name : Bilessglu

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            July 19, 2024

                            Lead Product(s) : Chiglitazar Sodium,Metformin

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Shenzhen Chipscreen Biosciences

                            China arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Shenzhen Chipscreen Biosciences

                            China arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Chidamide,Rituximab,Cyclophosphamide

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            NMPA Approves Chipscreen's Chidamide with R-CHOP for Diffuse Large B-Cell Lymphoma

                            Details : Chidamide (Epidaza®), an oral subtype-selective HDAC inhibitor, combined with R-CHOP, is approved by NMPA for treating DLBCL with positive MYC and BCL2 expression.

                            Brand Name : Epidaza

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            April 30, 2024

                            Lead Product(s) : Chidamide,Rituximab,Cyclophosphamide

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Shenzhen Chipscreen Biosciences

                            China arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Shenzhen Chipscreen Biosciences

                            China arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Chiglitazar Sodium

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Positive Results from Phase II Trial (CGZ203 Study) of Chiglitazar Monotherapy for NASH

                            Details : Bilessglu (chiglitazar sodium) is a novel peroxisome proliferator activation-related receptor pan-agonist, which is being evaluated for the treatment of non-alcoholic steatohepatitis.

                            Brand Name : Bilessglu

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            March 18, 2024

                            Lead Product(s) : Chiglitazar Sodium

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Shenzhen Chipscreen Biosciences

                            China arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Shenzhen Chipscreen Biosciences

                            China arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NWY001

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Chipscreen Doses First Patient in Phase 1 Trial of Bispecific Antibody NWY001 for Tumors

                            Details : NWY001 is world's first PD-1/CD40 bispecific antibody. It is currently being evaluated in phase 1 clinical trials for the treatment of patients with advanced solid tumors.

                            Brand Name : NWY001

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            January 16, 2024

                            Lead Product(s) : NWY001

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Shenzhen Chipscreen Biosciences

                            China arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Shenzhen Chipscreen Biosciences

                            China arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CS32582

                            Therapeutic Area : Dermatology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Chipscreen's New Drug Candidate CS32582 Capsules Approved for Clinical Treatment of Psoriasis

                            Details : CS32582 is a novel small molecule and highly selective allosteric inhibitor of Tyrosine Kinase 2 (TYK2). It got approval for conducting clinical trials for the treatment of psoriasis.

                            Brand Name : CS32582

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            November 02, 2023

                            Lead Product(s) : CS32582

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Shenzhen Chipscreen Biosciences

                            China arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Shenzhen Chipscreen Biosciences

                            China arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Chidamide

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Recipient : HUYA Bioscience International

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            HUYABIO International Receives Regulatory Approval for Hiyasta® Monotherapy of Peripheral T-Cell Lymphoma in ...

                            Details : Data from the registration study of HBI-8000 has demonstrated clinically meaningful responses despite the advanced stage of disease and acceptable safety profile to address an important unmet medical need in this patient population.

                            Brand Name : HBI-8000

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            November 30, 2021

                            Lead Product(s) : Chidamide

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Recipient : HUYA Bioscience International

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Shenzhen Chipscreen Biosciences

                            China arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Shenzhen Chipscreen Biosciences

                            China arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Chiauranib

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Chipscreen Received a Phase 1b/2 Clinical Trial of Chiauranib/CS2164 IND Clearance from the US Food and Drug A...

                            Details : Chiauranib is an innovative, 3-pathway targeted kinase small molecule inhibitor with high selectivity against Auroa B /VEGFRs/CSF1R currently entering Phase III clinical trials in China.

                            Brand Name : CS2164

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            April 16, 2021

                            Lead Product(s) : Chiauranib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Shenzhen Chipscreen Biosciences

                            China arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Shenzhen Chipscreen Biosciences

                            China arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CS12192

                            Therapeutic Area : Immunology

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Chipscreen Biosciences's Original New Drug CS12192: Investigational New Drug (IND) Application Accepted

                            Details : CS12192 showed significant efficacy in multiple autoimmune disease models in preclinical studies.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            March 24, 2020

                            Lead Product(s) : CS12192

                            Therapeutic Area : Immunology

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth